Molecular Weight(MW): 425.91
Domperidone is an oral dopamine D2 receptor antagonist, used to treat nausea and vomiting.
Purity & Quality Control
Choose Selective Dopamine Receptor Inhibitors
|Description||Domperidone is an oral dopamine D2 receptor antagonist, used to treat nausea and vomiting.|
Domperidone (a D2R antagonist) inhibits Equilibrative NT1 (ENT1) activity more in the presence than in the absence of Bromocriptine and displays an IC50 value lower than that of Bromocriptine or Ergovaline in Madin-Darby bovine kidney (MDBK) cells. 
|In vivo||Domperidone (0.1 mg/kg) results in a significant decrease in feeding behavior and stimulation of basal metabolism, but has no effect on locomotor activity of rats in a Phenomaster system.  Domperidone (1.1 mg/kg and 5.5 mg/kg, oral) significantly increases laminar microvascular blood flow (LMBF) in horses, compared with baseline values, beginning 4 hours after administration, and this effect persisted for at least 8 hours. Domperidone (0.2 mg/kg, i.v.) significantly increases laminar microvascular blood flow (LMBF) in horses, compared with baseline values, at 10 and 12 hours after administration.  Domperidone can ameliorate deleterious reproductive effects and reduce weight gain associated with fescue toxicosis in heifers.  Domperidone-treated mares have shorter gestation duration and foaled closer to their expected parturition date than did control mares. Domperidone-treated mares have higher Mammary gland scores and serum prolactin concentration.  Domperidone (5 mg/kg, oral) increases peak plasma acetaminophen concentration and area under the curve in rats, indicating increased gastric emptying. Domperidone decreases the dopamine-induced contractile activity of midjejunal longitudinal muscle strips in rats. |
-  Miles ED, et al. J Agric Food Chem,?011, 59(17), 9691-9699.
-  Sudakov SK, et al. Bull Exp Biol Med,?013, 155(6), 705-707.
-  Castro JR, et al. Am J Vet Res,?010, 71(3), 281-287.
|In vitro||DMSO||48 mg/mL (112.69 mM)|
|Ethanol||1 mg/mL (2.34 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02699385||Recruiting||Gastroenteritis||Janssen-Cilag International NV||June 2016||Phase 3|
|NCT02816853||Completed||Healthy||Janssen Research & Development, LLC||May 2016||Phase 1|
|NCT02980250||Enrolling by invitation||Feeding Intolerance|Premature Birth|Domperidone||Nanfang Hospital of Southern Medical University|Guangdong Provincial Maternal and Child Health Hospital|Shen-Zhen City Maternity and Child Healthcare Hospital|Maternal and Child Health Hospital of Foshan|Maternal and Child Health Hospital,Huadu District|Guangzhou Panyu Central Hospital||November 2015||Phase 4|
|NCT02493049||Enrolling by invitation||Multiple Sclerosis, Relapsing-Remitting||University of Calgary|Alberta Innovates Health Solutions||August 2015||Phase 2|
|NCT02757534||Recruiting||Gastroparesis||Assouline-Dayan, Yehudith|University of Iowa||May 2015||Phase 2|
|NCT02308137||Recruiting||Multiple Sclerosis, Secondary Progressive||University of Calgary|Alberta Innovates Health Solutions||February 2015||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.